中国肺移植现状与挑战

Current status and challenges of lung transplantation in China

摘要:

肺移植是终末期肺部疾病唯一有效的治疗策略。近四十年来，我国肺移植领域取得了较大进展，肺移植事业处于高速发展的新时代。在临床方面，我国肺移植手术数量及质量稳步上升，近7年共完成3 600例肺移植，具有肺移植资质机构达54所。在科研方面，我国肺移植临床研究数据首次发表于国际顶级期刊，基础研究团队也在多个肺移植关键领域取得重要成果，这表明我国肺移植临床工作及科研水平正逐渐达到国际前列。尽管我国肺移植已取得较大进步，但在团队建设、质量控制、标准流程及技术规范、专家共识和指南、肺移植数据注册及建库等方面仍面临着诸多瓶颈与挑战。本文旨在从临床及科研两方面综述我国肺移植现状，总结分析我国肺移植当前面临的主要挑战。

Abstract:

Lung transplantation (LTx) is the only effective treatment for patients with end-stage lung disease. The field of LTx has undergone tremendous progress over the past four decades in China. The domestic filed of LTx is in a new era of rapid development. Clinically, LTx is steadily increasing both in quantity and quality. It has been reported that 3 600 LTx have been successfully performed in the last 7 years, and 54 institutions have been accredited to perform LTx. In scientific research terms, the international top-tier journals have recently published clinical research data on LTx in China for the first time. In addition, several exciting breakthroughs have been made in basic research of LTx in China, indicating that both the clinical work and scientific research of LTx are gradually approaching the forefront worldwide. In spite of significant advancements, several challenges and bottlenecks remain, including the LTx team building, quality control, implement of standard procedure and technical specification, development of expert consensus and guideline, data registration, and database creating. This paper aims to review the current domestic status of LTx from both clinical and scientific researching perspectives, and afterwards analyze the main challenges faced.